Group items tagged

Lightweight Wheelchair is loaded with features and adjust ability. Almost everything can be customized to fit needs, from a height and position adjustable back to an adjusting rear axle. The semi-pneumatic spoke wheels not only look stylish, but provide a smooth and true roll, giving more control over where are going. This Ultra Lightweight Wheelchairs is available in two seat widths and with either swing away foot rests or elevating foot rests to fit needs. Ultralight manual wheelchair are essential for ensuring a user's ability to use their wheelchair in the most functional, efficient, and healthy way possible. For individuals who have utilized an ultralight manual wheelchair for a number of years, it is common for them to know exactly how their wheelchair should be set-up from the precise seat to floor height measurement and vertical position of the rear wheel. On the other hand, a newer user may require adjust ability to meet their changing needs over time as they continues to recover and/or adapt to using a wheelchair. Karma KM 2500 Small Wheel Wheelchair: Karma KM 2500 Small Wheel Wheelchair Specifications: Width 18" Front/Rear Wheels 6" to 14" Seat Width 47cm Seat Depth 40cm Overall Width 66cm Overall Collapsed Width 36cm Armrest Height 21cm Overall Length 90cm Seat Height 47cm Backrest Height 38cm Overall Height 86cm Weight 9.2 k.g. Karma KM 2500 Small Wheel Wheelchair Seat and Back: AEGIS Microbe Shield Approved by the FDA, EPA, EU, etc., bonded anti-microbial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms. It is a shield for your health. Karma KM 2500 Small Wheel Wheelchair Extended Armrest: By simulating the natural position of arms, the extended armrest design is ergonomic and creates bigger seating space. An Ultra lightweight wheelchair (9.2 kg) with a compact design for either attendant assisted or self propelling users. The use of aircr

Travel wheelchair assists people to become more mobile and independent. There are many different types of wheelchairs that are used for various reasons. It is important to understand the limitations and safe operation of whatever wheelchair choose or need. The travel chair seat size (width and depth), seat-to-floor height, footrests/leg rests, front caster outriggers, adjustable backrests, controls, and many other features can be customized on, or added to, many basic models, while some users, often those with specialized needs, may have wheelchairs custom-built. A single-arm drive enables the user to turn either left or right while the two-armed drive enables user to move forward or backward on a straight line. Another type of wheelchair commonly used is a lever-drive wheelchair. This type of chair enables the user to move forward by pumping the lever back and forth. Travel Wheelchair is designed with unique S shaped seat which provides pressure relief and prevents slippage. Equipped with wide arm pads the wheelchair provides extra support for the user. The chair material is treated with an Aegis Microbe shield to reduce the likelihood of staining and odours. Streamline oval tubes add style and strength to the wheelchair whilst the aluminium frame keeps the chair light. Also featured are new patented footrests which swing both outwards and inward for user convenience. Karma KM 2500 Small Wheel Wheelchair: Karma KM 2500 Small Wheel Wheelchair Specifications: Width 18" Front/Rear Wheels 6" to 14" Seat Width 47cm Seat Depth 40cm Overall Width 66cm Overall Collapsed Width 36cm Armrest Height 21cm Overall Length 90cm Seat Height 47cm Backrest Height 38cm Overall Height 86cm Weight 9.2 k.g. Karma KM 2500 Small Wheel Wheelchair Seat and Back: AEGIS Microbe Shield Approved by the FDA, EPA, EU, etc., bonded anti-microbial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms.

Tynor R O M Knee Brace Prefabricated, custom adjusted R.O.M. Knee Brace controls and restrict flexion/extension of the knee joint through a multi-point joint fixation system to allow a range of motion or immobilization to the knee. Universal design allows it to be used on quite a big range of population and for a multiple orthopedic problems associated with knee joint. Immobilization at any angle Controlled motion between any two angles Quick and easy application and removal. Tynor R O M Knee Brace Features R.O.M. Dial 0 to 120 degree flexion. 0 to 60 degree hyper extention Locking at any angle or motion between any two angles possible Interval of 10 to15 degrees Pleasurable locking, using easy pull mechanism Neoprene Liner with Silicone Coating Enhanced product grip Less slippage of product High cushioning coefficient and more comfort Less discomfort of tight straps Ergonomic Design Light in weight Bilateral symmetrical Improved patient compliance Easy removal and application Universal design, one size fits all Straps with Reverse Buckle Mechanism Enhanced grip Easy to wear Controlled tightening.

Pharmaceutical Services Negotiating Committee (PSNC) has launched two surveys to gather data on the pressures that people working in community pharmacies are facing. Pharmacy teams have informed the negotiator about the ongoing financial and operational pressures and expressed concerns that these pressures could impact patients' care. The surveys would give a snapshot of the problems faced by pharmacies and the results will be used in ongoing discussions with NHS England & NHS Improvement and the Department of Health and Social Care. The results will also help PSNC to make pharmacy's case in conversations with the MPs, ministers and the national media. The two separate surveys are for: Pharmacy business owners/head office representatives - This survey covers the pressures faced by businesses, including financial and staffing pressures. Pharmacy teams - It covers the day-to-day pressures experienced by pharmacy teams including supply chain issues, patient interactions/experience and staff morale.

The World Health Organization says it is tracking a few dozen cases of two new sub-variants of the highly transmissible Omicron strain of the coronavirus to assess whether they are more infectious or dangerous. It has added BA.4 and BA.5, sister variants of the original BA.1 Omicron variant, to its list for monitoring. It is already tracking BA.1 and BA.2 - now globally dominant - as well as BA.1.1 and BA.3. The WHO said on Monday (April 11) it had begun tracking them because of their "additional mutations that need to be further studied to understand their impact on immune escape potential". Viruses mutate all the time but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause. For instance, BA.2 now represents nearly 94% of all sequenced cases and is more transmissible than its siblings, but the evidence so far suggests it is no more likely to cause severe disease.

Digital pharmacy app Charac has raised over £1 million in debt and equity, bringing total funding to date for the London-based startup to £2.5m. Pharmacy Business understands while the majority of the new finance, worth about £1.2 million, comes from the National Pharmacy Association (NPA) coffer, the remainder is put forward by a number of individual pharmacy businesses. The pharmacy sector is in a state of crisis, experiencing nearly two closures per week over the past two years, Charac said in a statement. According to data from the NHS Business Services Authority, there are now only 11,026 community pharmacies in England, the lowest number since 2015. The current crisis is attributed to escalating operational costs, a shortage of staff, and diminished government financial support.

The lessons from Covid crisis applied in the future through collaboration can create a better integration between GP practices, hospitals and community pharmacies, Pharmacists Defence Association (PDA) has proposed. Stating that a more integrated healthcare system could enable pharmacists to provide effective and more efficient care to patients, the PDA proposed a model where at least two pharmacists would be working in each community pharmacy, empowered, and enabled with two-way referral pathways, having more clinical input and full access to patient records. "Such an environment could not only help to improve communications between health professionals and increase access to services for patients, but would support the NHS to operate more effectively."

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

Over the past two years, the Covid pandemic has resulted in a backlog of elective care within the NHS, with record numbers of patients on waiting lists across the UK. Despite efforts to catch up after the first wave, subsequent waves have put further strain on an already stretched NHS system. This has had a tremendous impact on many patients waiting for routine dermatology appointments and, while every effort has been made to see patients with suspected serious skin cancers within two weeks, this target is not always achieved. With rising waiting times, pharmacists are increasingly the first port of call for patients suffering with a broad range of skin problems. From acne and rosacea, eczema or psoriasis, to changing skin lesions or simple insect bites, pharmacists can give helpful advice, allowing some customers to find quick relief to their skin complaint in mild cases, while directing others to see their GP without delay. Below is some practical advice that pharmacists can give to their customers with commonly encountered skin complaints. Acne Acne is a common skin condition that not only affects teenagers but adults too. It is estimated that up to 40 per cent of women continue to suffer with acne into their adult years. Acne has been linked to an increased incidence of depression, anxiety and even suicidal ideation. Patients have reported feeling overlooked and often dismissed in their concerns by health care professionals. Unfortunately, these issues have been further compounded by delays in being seen and treated due to the ongoing Covid pandemic. Pharmacists are well placed to help acne patients choose the right skincare. This should consist of lightweight products, such as gel or milky cleansers, with moisturisers in serum, lotion or light cream preparations. Some acne suitable products are further labelled as non-comedogenic. Oil-based or occlusive preparations are best avoided. There are many good quality, non-comedogenic sun blocks suited

The General Pharmaceutical Council (GPhC) has revealed it has received 25 whistleblowing disclosures between April 2021 and March 2022. The pharmacy regulator said, in its annual report, that it has concluded enquiries on 22 disclosures so far with a further three still under review. "We also concluded two qualifying disclosures that were raised during the previous reporting period," it said, adding: "The action GPhC took included a full investigation through established fitness to practise processes and follow-up action through its inspection network. "The former can result in any available outcome throughout the fitness to practise process. The latter can include guidance, a follow-up visit or an unexpected inspection." 12 concerns were investigated and concluded with no further action. Three were signposted to another organisation. The remaining seven cases were concluded by sharing information with inspection colleagues for follow up action. Of the two concerns from the previous reporting period, one was concluded with no further action and the other remains under investigation.

Pfizer said on Thursday (June 1) data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia. Hospital-acquired pneumonia occurs in patients at least two to three days after being admitted, or in those who have life-threatening lung infections with high mortality rates and who are on mechanical breathing machines. Pfizer said the data from the studies shows the antibiotic combination of ATM-AVI is effective and well-tolerated in treating infections caused by gram-negative bacteria. The cure rate in patients with complicated intra-abdominal infections with Pfizer's combination therapy, along with existing generic drug metronidazole, was 76.4%, versus 74% using the other antibiotics.

As part of a new blueprint for primary care, the government today (May 9) announced an investment of £645 million over two years to expand community pharmacy services in England. In a statement, NHS England said: "For the first time ever, patients who need prescription medication will be able to get it directly from a pharmacy, without a GP appointment, for seven common conditions including earache, sore throat, or urinary tract infections." Prime minister Rishi Sunak hopes that the measures will help end the "all-too stressful wait on the end of the phone for patients" by freeing up 15 million slots at doctors' surgeries over the next two years. "We will end the 8am rush and expand the services offered by pharmacies, meaning patients can get their medication quickly and easily," he said Almost half a million women will no longer need to speak to a practice nurse or GP to access oral contraception and will instead be able to pop into their local pharmacy for it, according to the government announcement. Blood checks for people suffering from moderate risk of heart attack or stroke conducted in community pharmacies will more than double from 900,000 last year to 2.5 million next year. NHS chief executive Amanda Pritchard said the "ambitious package" would help transform how care is provided within the health service "with pharmacies playing a central role in managing the nation's health including providing lifesaving checks and medication for common conditions for the first time.

Homecare.co.uk's famed Top 20 UK awards have turned out a multiple winner, with Blue Angel Care a highlight. Blue Angel Care took two prestigious gongs , Top 20 Homecare Group Provider in the UK and Top 20 Home Care Providers in South East England. Finding innovative ways to circumnavigate the difficulties of the coronavirus pandemic, the homecare specialists have grown to a nationwide team of more than 200 care givers. Dariusz Motka, Managing Director and Co-Founder of Blue Angel Care, said in a statement: "We are eternally grateful to the readers and reviewers of Homecare.co.uk for honouring us with, not one, but two awards." Praising his staff, Dariusz added : "More so, we are all grateful to the incredibly hardworking and professional staff that help to train so many capable carers every single week."

Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health. A CLOSER LOOK AT DIABETES Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D). Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes. Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin therapy to manage type 2 diabetes. GLP-1 RECEPTOR AGONISTS A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.

French drugmaker Sanofi said on Monday (June 13) an upgraded version of the Covid-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot. While the two companies' first experimental Covid shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is moulded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations. Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna. In a separate trial conducted by a French hospitals network, Sanofi's Beta-adapted booster shot triggered a higher immune response than Sanofi's first-generation shot or Pfizer-BioNTech's established vaccine in previously vaccinated volunteers.

The drug, 'durvalumab', can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years. It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling it out. The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy and radiotherapy concurrently. NHS said: "The drug can stop the cancer from getting worse for more than two years - significantly longer than treatment with a combination of chemotherapy and radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their loved ones." Dame Cally Palmer, national cancer director for NHS England, said: "We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer - giving them more precious time with family and friends.

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

Have you ever wondered about the health benefits of ginseng? It's been used for thousands of years by people in Asia and Eastern Europe, but did you know it's good for more than just boosting energy? The ginseng plant deals with 11 combinations of short, slowly growing plants with fleshy roots. It can revive and improve well-being. This article will explore how this herbal plant can benefit your body. 11 Health Benefits of the Ginseng Plant There are two types of ginseng plants mainly: Asian or Korean ginseng (Panax ginseng) American ginseng (Panax quinquefolius). Studies have discovered that the distinct types have various uses. American ginseng is believed to be less stimulating in traditional Chinese medicine than the Asian one. There are several other herbs known as ginseng, like eleuthero or Siberian ginseng, but they don't have the valuable content of ginsenosides. Ginseng has traditionally been used for several medical illnesses. However, its benefits for most of them have yet to be thoughtfully researched. These include: 1/11_It may help your lungs work better. ginseng plant lowers lungs infections.Ginseng may also help your lungs, according to a published study in the Journal of Ethnopharmacology. Researchers found that one of the active ingredients in ginseng, ginsenoside Rg1 has an anti-inflammatory effect on the lungs and can even protect against asthma and bronchitis. They found that rats with asthma had less inflammation after being given doses of ginseng for two weeks compared to rats not given any. They also observed that rats with pneumonia had fewer symptoms when they were treated with inhaled doses of ginsenoside Rg1 or orally administered doses of Korean red ginseng extract (KRGE). 2/11_It may lower blood sugar levels. ginseng plant lower blood sugar levels. It's not just your imagination-ginseng can help lower blood sugar levels in people with diabetes. It also has been proven to reduce the amount of cholesterol in your body. It

Benefits of Echinacea for Health and Wellness The Echinacea plant is still in benefit today as a dietary supplement. It has nine species, but only two of them, Echinacea purpurea and Echinacea angustifolia are generally used in supplements. Other supplements are in pill form, teas, juices, and creams. It possesses many compounds that may benefit your health. 1/10_ It treat infections and wounds Echinacea has been used for centuries to treat infections and wounds. In fact, the Native Americans used echinacea to treat their cuts, burns, bruises, and insect bites. They'd apply the fresh plant directly onto their skin to heal those wounds faster than they would have otherwise. It has also been shown in multiple studies to be effective in treating colds and other infections. This benefit is believed to be due to its immune-boosting properties that help strengthen your body's defenses against bacteria. ECZEMA People with eczema suffer from an inflammation of the skin; a cream including echinacea extract may benefit. Early research suggests that daily topical application of echinacea cream helped alleviate eczema-related irritation. It also helped create the protective outer layer of skin. Be aware of probable allergic reactions, as people with eczema generally have allergies and asthma. 2/10_Antioxidant powerhouse Antioxidants are substances that protect you from disease by neutralizing or eliminating the damaging effects of free radicals. Free radicals are atoms, molecules, or ions in your body that have an unpaired electron and can cause oxidative stress in your cells. Echinacea is a powerful antioxidant that helps fight the free radicals that cause damage to cells and tissues. Free radicals may contribute to cancer development, cardiovascular disease, arthritis, diabetes mellitus, Alzheimer's disease, and many other chronic diseases. Echinacea has been shown in studies to positively impact the immune system by boosting its response against infection-causing

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare professional.' The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022. In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data and asked for advice from the independent Commission on Human Medicines (CHM). "The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no other effective or tolerated treatment," said MHRA. "Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective or tolerated treatment or the risks do not apply."